603233 Stock Overview
Manufactures, wholesales, and retails pharmaceutical products in China. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
DaShenLin Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥15.30 |
52 Week High | CN¥27.10 |
52 Week Low | CN¥11.92 |
Beta | 0.34 |
11 Month Change | 2.34% |
3 Month Change | 18.70% |
1 Year Change | -40.51% |
33 Year Change | -37.75% |
5 Year Change | -37.14% |
Change since IPO | -12.15% |
Recent News & Updates
Recent updates
Shareholder Returns
603233 | CN Consumer Retailing | CN Market | |
---|---|---|---|
7D | -5.0% | -0.2% | -0.6% |
1Y | -40.5% | -14.2% | 3.2% |
Return vs Industry: 603233 underperformed the CN Consumer Retailing industry which returned -15.3% over the past year.
Return vs Market: 603233 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
603233 volatility | |
---|---|
603233 Average Weekly Movement | 8.2% |
Consumer Retailing Industry Average Movement | 7.9% |
Market Average Movement | 8.4% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 603233 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603233's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 45,466 | Guoqiang Ke | www.dslyy.com |
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. It provides Chinese and western patent medicines, ginseng tonic medicinal materials and Chinese herbal pieces, health care products, medical equipment, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
DaShenLin Pharmaceutical Group Co., Ltd. Fundamentals Summary
603233 fundamental statistics | |
---|---|
Market cap | CN¥17.42b |
Earnings (TTM) | CN¥850.26m |
Revenue (TTM) | CN¥26.54b |
20.5x
P/E Ratio0.7x
P/S RatioIs 603233 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603233 income statement (TTM) | |
---|---|
Revenue | CN¥26.54b |
Cost of Revenue | CN¥17.53b |
Gross Profit | CN¥9.01b |
Other Expenses | CN¥8.16b |
Earnings | CN¥850.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.75 |
Gross Margin | 33.95% |
Net Profit Margin | 3.20% |
Debt/Equity Ratio | 55.8% |
How did 603233 perform over the long term?
See historical performance and comparison